Changes in quality of life in the first 5 years of disease in a multicenter cohort of patients with systemic lupus erythematosus.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Gladman, D D
Bae, S C
Fortin, P R
Hanly, J G
Wallace, D J
Alarcón, G S
Bruce, I N
van Vollenhoven, R
Romero Diaz, J
Journal titleArthritis care & research
Publication Begin page1374
Publication End page9
MetadataShow full item record
AbstractThe Medical Outcomes Study Short Form 36 (SF-36) is recommended to assess quality of life (QOL) in systemic lupus erythematosus (SLE). The aim of the current study was to assess QOL over time in the first 5 years of a multicenter inception cohort of patients with SLE.
An inception SLE cohort was assembled according to a standardized protocol between 2000 and 2012. In addition to clinical and laboratory assessments, patients completed the SF-36 at yearly intervals. Only patients who had ≥5 completed QOL questionnaires were included in these analyses. Generalized estimating equation models were run separately for each of the 8 subscales and for the physical and mental component summary scores, adjusting for repeated measures by patients.
A total of 495 patients were included. The mean ± SD disease duration at the first visit was 5.3 ± 4.1 months. The mean ± SD age at enrollment was 35.8 ± 13.2 years. All 8 subscales and the 2 summary scores showed improvement in the first 2 years from enrollment. Between years 2 and 5, none of the subscales or summary scores showed any change. Minimum clinically important improvement was achieved by 35-56% of the patients and was influenced by demographic and disease factors.
Unlike late-stage lupus, where QOL is stable over time, in patients with early disease, all subscales improve in early followup up to 2 years. Therefore, the SF-36 may be a sensitive outcome measure in early disease in patients with SLE.
CitationUrowitz M, Gladman DD, Ibañez D, Sanchez-Guerrero J, Bae SC, Gordon C, Fortin PR, Clarke A, Bernatsky S, Hanly JG, Wallace DJ, Isenberg D, Rahman A, Merrill J, Ginzler E, Alarcón GS, Fessler B, Khamashta M, Steinsson K, Petri M, Dooley M, Bruce IN, Manzi S, Sturfelt G, Nived O, Ramsey-Goldman R, Zoma A, Maddison P, Kalunian K, van Vollenhoven R, Aranow C, Romero Diaz J, Stoll T. Changes in quality of life in the first 5 years of disease in a multicenter cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2014 Sep;66(9):1374-9. doi: 10.1002/acr.22299. PMID: 24497416.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Copyright © 2014 by the American College of Rheumatology.
- Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus?
- Authors: Touma Z, Gladman DD, Ibañez D, Urowitz MB
- Issue date: 2011 Sep
- Responsiveness of the 36-item Short Form Health Survey and the Lupus Quality of Life questionnaire in SLE.
- Authors: Devilliers H, Amoura Z, Besancenot JF, Bonnotte B, Pasquali JL, Wahl D, Maurier F, Kaminsky P, Pennaforte JL, Magy-Bertrand N, Arnaud L, Binquet C, Guillemin F, Bonithon-Kopp C
- Issue date: 2015 May
- Long-term outcome of early neuropsychiatric events due to active disease in systemic lupus erythematosus.
- Authors: Wang M, Gladman DD, Ibañez D, Urowitz MB
- Issue date: 2012 Jun
- Impaired health status and the effect of pain and fatigue on functioning in clinical trial patients with systemic lupus erythematosus.
- Authors: Petri M, Kawata AK, Fernandes AW, Gajria K, Greth W, Hareendran A, Ethgen D
- Issue date: 2013 Nov
- Can health utility measures be used in lupus research? A comparative validation and reliability study of 4 utility indices.
- Authors: Moore AD, Clarke AE, Danoff DS, Joseph L, Bélisle P, Neville C, Fortin PR
- Issue date: 1999 Jun